Zacks: Replimune Group Inc (REPL) Given Consensus Rating of “Buy” by Brokerages

Replimune Group Inc (NASDAQ:REPL) has been given an average broker rating score of 1.67 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. Replimune Group’s rating score has declined by 67% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.

Analysts have set a twelve-month consensus price objective of $27.33 for the company and are anticipating that the company will post ($0.35) EPS for the current quarter, according to Zacks. Zacks has also assigned Replimune Group an industry rank of 55 out of 255 based on the ratings given to its competitors.

A number of research analysts have commented on REPL shares. Zacks Investment Research lowered Replimune Group from a “hold” rating to a “sell” rating in a research report on Saturday, March 16th. JPMorgan Chase & Co. lowered Replimune Group from an “overweight” rating to a “neutral” rating in a research report on Wednesday, January 23rd.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Redmile Group LLC purchased a new stake in shares of Replimune Group in the 3rd quarter worth approximately $35,307,000. FMR LLC bought a new position in Replimune Group in the 3rd quarter worth $7,773,000. BlackRock Inc. bought a new position in Replimune Group in the 3rd quarter worth $6,411,000. Norges Bank bought a new position in Replimune Group in the 4th quarter worth $3,350,000. Finally, Vanguard Group Inc bought a new position in Replimune Group in the 3rd quarter worth $5,379,000. 57.38% of the stock is owned by institutional investors and hedge funds.

REPL stock traded down $0.19 during mid-day trading on Tuesday, hitting $15.11. 40,087 shares of the stock were exchanged, compared to its average volume of 109,116. The company has a quick ratio of 38.14, a current ratio of 38.14 and a debt-to-equity ratio of 0.03. Replimune Group has a 12 month low of $8.88 and a 12 month high of $23.55.

Replimune Group (NASDAQ:REPL) last released its earnings results on Thursday, February 14th. The company reported ($0.24) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.24). On average, sell-side analysts forecast that Replimune Group will post -1.31 EPS for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

See Also: What Does Beta Mean In Stock Selection

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.